---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-080247"
form_type: "8-K"
ticker: "RAPP"
cik: "0002012593"
company_name: "Rapport Therapeutics, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T03:23:33.482308+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# RAP-219 Phase 2a fully enrolled; topline data Sept 2025; safety profile clean

## Summary
- Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled; topline results expected September 2025.
- Consolidated Phase 1 safety data (n=64) shows all TEAEs Grade 1/2, no SAEs; common: headache, dry mouth, brain fog, fatigue.
- Upcoming catalysts: initiate Phase 2a in bipolar mania Q3 2025, update on diabetic neuropathic pain program 2H 2025.
- Cash, cash equivalents and short-term investments of $285.4M as of March 31, 2025; runway through end of 2026.

## SEC filing metadata
- accession: 0000950170-25-080247
- form_type: 8-K
- ticker: RAPP
- cik: 0002012593
- company_name: Rapport Therapeutics, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2012593/000095017025080247/0000950170-25-080247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2012593/000095017025080247/rapp-20250602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-080247
- JSON: https://secwatch.observer/filing/0000950170-25-080247.json
- Plain text: https://secwatch.observer/filing/0000950170-25-080247.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.